Daniel Griffin

Placeholder Person Graphic
Amgen
Principal Engineer and Sr. Manager
Daniel J. Griffin is a Principal Engineer and Senior Manager at Amgen in Pivotal and Commercial Synthetics Drug Substance Process Development. At Amgen, Dan contributes to the commercial process development, process characterization, technology transfer, and process validation for Amgen’s synthetic portfolio. He also leads a number of technical advancement pillars for synthetic drug substance process development engineering, including digital strategy and continuous manufacturing. Prior to joining Amgen, Dan earned a PhD in chemical engineering from Georgia Institute of Technology under Professors Martha Grover, Yoshi Kawajiri, and Ronald Rousseau, with his primary research focused on the topic of controlling salt crystallization from nuclear waste.

Related Articles

Continuous Manufacturing of Small Molecule Drug Substances
Online Exclusives
Continuous Manufacturing of Small Molecule Drug Substances

The adoption of continuous manufacturing (CM) in the pharmaceutical industry is increasing because of the advantages and opportunities it offers, including the ability to handle hazardous reactions, a higher degree of process integration, and improved sustainability. This article discusses the considerations and approaches adopted by Pfizer, Eli Lilly, GSK, and Amgen in designing and...

Contrasting Drug Substance and Drug Product Continuous Manufacturing
iSpeak Blog
Contrasting Drug Substance and Drug Product Continuous Manufacturing

Continuous manufacturing (CM) is gaining traction in pharmaceutical manufacturing. The purpose of this post is to highlight some of the differences between small molecule Drug Substance (DS) and Drug Product (DP) continuous manufacturing (CM), which may be helpful in considering the development and execution of CM for pharmaceutical manufacturing. The following are the key differences from our...